deltatrials
Completed PHASE3 INTERVENTIONAL 6-arm NCT03214367

A Study of LY900014 in Participants With Type 1 Diabetes (PRONTO-T1D)

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D

Sponsor: Eli Lilly and Company

Conditions Type 1 Diabetes Mellitus
Interventions Insulin Degludec Insulin Glargine Insulin Lispro LY900014
Updated 22 times since 2017 Last updated: Apr 17, 2020 Started: Jul 17, 2017 Primary completion: Sep 6, 2018 Completion: Aug 22, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03214367, this PHASE3 trial focuses on Type 1 Diabetes Mellitus and remains completed. Sponsored by Eli Lilly and Company, it has been updated 22 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Oct 2019 · 9 months · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jun 2020 · 7 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 9 months · monthly snapshot

Change History

22 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 17 earlier versions

  1. Jun 2020 — Jan 2021 [monthly]

    Completed PHASE3

  2. Nov 2019 — Jun 2020 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Oct 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE3

  4. Jan 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

  5. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  6. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Jul 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  10. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  11. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE3

  12. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE3

  13. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE3

  14. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE3

  15. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  16. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  17. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Allentown, United States , Alzira, Spain , Amagasaki, Japan , Ampelokipoi, Greece , Arkhangelsk, Russia , Athens, Greece , Atlanta, United States , Auckland, New Zealand , Aurora, United States and 134 more locations